The new year starts with momentum in medical innovation. Funding across surgical robotics, AI-driven imaging, and neuromodulation signals strong investor confidence and sets the stage for significant advances in patient care in 2026. Details follow below.
Surgerii Robotics raised $100M to take single-port surgical robotics system global
The company will use the Series D financing to market its Shurui single-port surgical robot both domestically and internationally, as well as to accelerate the production of its next-generation products.
Loyal Valley Capital, a private equity firm focusing on healthcare and technology innovations, led the round. Other participants included Shanghai Healthcare Capital, V Star Capital and DNV Capital, both specializing in healthcare innovations, and Hefei Industrial Investment.
CEO Kai Xu
Last week’s tracker: Medline, Olympus & more
Spiro Medical raised $67M Series A to support neuromod tech
Financing for the pulmonary neuromodulation system came from a syndicate led by Andera Partners, Omega Funds and Sherpa Healthcare Partners. HSG, Supernova Invest, Northern Light Venture Capital and Hero Inc. Ltd UK joined as well.
Spiro plans to use proceeds to develop its PNM system and execute on clinical work to pursue regulatory approval in the U.S.
CEO Rinda Sama
Biobeat secured $50M Series B financing
The Series B equity financing was led by new investors Ally Bridge Group, OrbiMed Advisors and Elevage Medical and included participation from a strategic investor.
Proceeds from the financing will be used to expand commercialization in the United States.
CEO Arik Ben Ishay
FineHeart secured additional €35M to support its growth
In total, the company has secured €83 million in financing, combining private capital and non-dilutive European public funding to accelerate the industrialization and clinical development of FlowMaker and establish itself as a future European AIMD leader.
This first €35 million closing brings together new investors, including Groupe Pasteur Mutualité and Groupe Etchart, alongside significant participation from the European Innovation Council (EIC)’s EIB fund. Existing investors – FH Founders, Lurra, IRDI, Groupe Doliam and NACO – also joined.
Co-Founder and CEO Arnaud Mascarell
ViCentra closed $13M extension, brought Series D to $98M
The financing includes new capital from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech. Existing investor Innovation Industries also took part in the second closing.
The company intends to use funds to scale manufacturing and deepen execution in Germany, the Netherlands and France. It also hopes to accelerate preparations to bring its next-generation Kaleido insulin patch pump to the U.S. market.
CEO Tom Arnold
BrightHeart raised €11M Series A to scale AI platform for prenatal ultrasound
The round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and founding investor Sofinnova Partners, as well as prominent clinicians and angel investors.
This financing will support U.S. commercialization, expansion across Europe, and relentless product innovation, scaling the B-Right AI Platform to set a new global standard of care in prenatal ultrasound.
CEO Cécile Dupont
MyndTec completed additional tranche of non-brokered private placement
The completion of the Current Tranche brings the aggregate Units issued to date under the Offering to 5,337,323 for aggregate gross proceeds under the Offering to $1,067,493.40.
The company intends to use the net proceeds for general corporate purposes, including working capital, corporate development, development of machine learning models, settlement of outstanding debt obligations, investor relations and marketing.
CEO Craig Leon
